Pharmacokinetic Behavior and Biodistribution of Paclitaxel-Loaded Lipid Nanosuspension
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최성업 | - |
dc.contributor.author | Jung Min Park | - |
dc.contributor.author | Woo Sik Choi | - |
dc.contributor.author | 이재휘 | - |
dc.contributor.author | 최영욱 | - |
dc.date.available | 2019-08-13T07:00:36Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 2093-5552 | - |
dc.identifier.issn | 2093-6214 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/33335 | - |
dc.description.abstract | In this study, paclitaxel-loaded lipid nanosuspension (PxLN) was prepared and the in vivo profiles after intravenous administration in rats were investigated. We compared the manufacturing processes depending on the temperature: PxLN-H for a hot homogenization process and PxLN-C for solidification of lipid-drug mixtures by liquid nitrogen. Both formulations showed submicron size distribution and the similar drug loading efficiency of about 70%. In vitro release of PxLNs and Taxol® performed by a dialysis diffusion method showed similar pattern for PxLN-H and Taxol®, but the reduced release profile for PxLN-C. PxLN or Taxol® was intravenously administered to the rats at a dose of 5 mg/kg as paclitaxel. The drug in blood samples were assayed by the HPLC/MS/MS method. The AUCt of PxLN-H was 3.4-fold greater than that of Taxol®. PxLN-H gave higher biodistribution in all tissues than did Taxol®. In addition, it maintained the higher drug concentration for 12 h. This lipid nanosuspension might be a promising candidate for an alternative formulation for the parenteral delivery of poorly water-soluble paclitaxel. | - |
dc.format.extent | 8 | - |
dc.publisher | 한국약제학회 | - |
dc.title | Pharmacokinetic Behavior and Biodistribution of Paclitaxel-Loaded Lipid Nanosuspension | - |
dc.type | Article | - |
dc.identifier.bibliographicCitation | Journal of Pharmaceutical Investigation, v.39, no.5, pp 359 - 366 | - |
dc.identifier.kciid | ART001385071 | - |
dc.description.isOpenAccess | N | - |
dc.citation.endPage | 366 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 359 | - |
dc.citation.title | Journal of Pharmaceutical Investigation | - |
dc.citation.volume | 39 | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Paclitaxel | - |
dc.subject.keywordAuthor | Lipid Nanosuspension | - |
dc.subject.keywordAuthor | Pharmacokinetic Behavior | - |
dc.subject.keywordAuthor | Biodistribution | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.